CDK9 and cancer: Recently, it was reported that combining PROTAC with a drug efflux protein (MDR) inhibitor can achieve durable protein degradation and a therapeutic response in cancer.137 Combination therapy may be a promising strategy to improve the efficacy of selective CDK9 inhibitors and degraders in tumors.